|Systematic (IUPAC) name|
|Legal status||℞ Prescription only|
|(what is this?)|
Sitafloxacin (INN; also called DU-6859a) is a fluoroquinolone antibiotic that shows promise in the treatment of Buruli ulcer. The molecule was identified by Daiichi Sankyo Co., which brought ofloxacin and levofloxacin to the market. Sitafloxacin is currently marketed in Japan by Daiichi Sankyo under the tradename Gracevit.
- Keating GM (April 2011). "Sitafloxacin: in bacterial infections". Drugs 71 (6): 731–44. doi:10.2165/11207380-000000000-00000. PMID 21504249.
- (Japanese) Gracevit グレースビット (PDF) Daiichi Sankyo Co. January 2008.
|This systemic antibacterial-related article is a stub. You can help Wikipedia by expanding it.|